HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 281, Issue 7, 4094-4099, February 17, 2006

This Article Full Text Full Text (PDF) All Versions of this Article: 281/7/4094    most recent M507028200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Haraguchi, K. Articles by Akiyama, T. Search for Related Content PubMed PubMed Citation Articles by Haraguchi, K. Articles by Akiyama, T.

Role of the Kinesin-2 Family Protein, KIF3, during Mitosis^*

Keiko Haraguchi, Tomoatsu Hayashi, Takeshi Jimbo¹, Tadashi Yamamoto, and Tetsu Akiyama²

From the Laboratory of Molecular and Genetic Information, Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-0032 and the Division of Oncology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan

During mitosis, kinesin and dynein motor proteins play critical roles in the equal segregation of chromosomes between two daughter cells. Kinesin-2 is composed of two microtubule-based motor subunits, KIF3A/3B, and a kinesin-associated protein known as KAP3, which links KIF3A/3B to cargo that is carried to cellular organelles along microtubules in interphase cells. We have shown here that the kinesin-2 complex is localized with components of the mitotic apparatus such as spindle microtubules and centrosomes. Furthermore, we found that expression of a mutant KIF3B, which is able to associate with KIF3A but not KAP3 in NIH3T3 cells, caused chromosomal aneuploidy and abnormal spindle formation. Our data suggested that the kinesin-2 complex plays an important role not only in interphase but also in mitosis.

Received for publication, June 28, 2005 , and in revised form, November 14, 2005.

^* This work was supported by grants-in-aid for scientific research on priority areas and the Organization for Pharmaceutical Safety and Research. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Present Address: New Product Research Laboratories III, Daiichi Pharmaceutical Co., Ltd., Tokyo R&D Center, Tokyo 134-0081, Japan.

² To whom correspondence should be addressed. Tel.: 81-3-5841-7834; Fax. 81-3-5841-8482; E-mail: akiyama{at}iam.u-tokyo.ac.jp.